A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab
https://www.facingourrisk.org/research-clinical-trials/study/66/parp-inhibitor-alone-or-plus-immunotherapy-for-advanced-brca-associated-breast-cancer
Clinicaltrials.gov identifier:
NCT02849496 (https://clinicaltrials.gov/show/NCT02849496)
Study Contact Information:
For additional information, please contact: Jamison Langguth by phone at: 203-4647261 or by email.
About the Study
This is a study for women or men who have been diagnosed with advanced breast cancer with a BRCA 1/2 mutation. The goal of this study is to look at whether giving the DNA damage repair inhibitor (PARP inhibitor) olaparib (Lynparza) in combination with the immunotherapy atezolizumab (Tecentriq) improves outcomes for patients compared to olaparib alone. NOTE: This study is no longer enrolling people.
This Study is Open To:
NOTE: This study is no longer enrolling people.
This Study is Not Open To:
NOTE: This study is no longer enrolling people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.